Patents by Inventor Michael Louis DOYLE

Michael Louis DOYLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies Binding to Human PAD4 and Uses Thereof
    Publication number: 20240132622
    Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.
    Type: Application
    Filed: July 20, 2023
    Publication date: April 25, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
  • TREATING RHEUMATOID ARTHRITIS
    Publication number: 20230310409
    Abstract: Disclosed is a method of treating rheumatoid arthritis, comprising administering to a patient a therapeutically effective dose of a TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TNF? inhibitor.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 5, 2023
    Inventors: Gary L. Schieven, Shailesh Dudhgaonkar, Michael Louis Doyle
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220348625
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 3, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
  • Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
    Patent number: 11359000
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mary Struthers, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
    Patent number: 10787494
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mary Struthers, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190359672
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: June 7, 2019
    Publication date: November 28, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190300592
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA